Recce Pharmaceuticals (ASX:RCE) received a notice of allowance from the Japan Patent Office for Patent Family 4 for its anti-infectives, according to a Wednesday filing with the Australian bourse.
The claims relate to RECCE 327 and RECCE 529, which are both designed to treat bacterial and viral infections. The patent will expire in 2041.
Recce Pharmaceuticals' shares were down past 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.